Prof Ribas speaks with ecancer at WIN 2017 about "the canary in the mine" of PDL-1 expression on tumour cells, and their response to checkpoint therapy.
He notes the off-target toxicities of ipilimumab, and the rationale for combining therapies to increase T cell infiltration beyond CTLA-4.
Prof Ribas notes the importance of the tumour microbiome in determining immunotherapy response, and the differing outcomes of adjuvant vs neoadjuvant staging.
- New biomarkers for response to immunotherapy ( Download)
- Predicative biomarkers of response to immunotherapy in STS ( Download)
- Dr. Levy on Biomarkers of Response to Immunotherapy ( Download)
- A new trial design for immunotherapy strategies and biomarkers of response ( Download)
- Dr. Levy on Investigational Biomarkers of Response to Immunotherapy in NSCLC ( Download)
- Predictive biomarkers of response to immunotherapy in soft tissue sarcoma ( Download)
- Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment ( Download)
- Dr. Dreicer on Biomarkers of Response to Immunotherapy in Urothelial Cancer ( Download)
- Biomarkers in Cancer Immunotherapy: How Much Do They Matter ( Download)
- Dr. Sabari on Biomarkers of Response to Immunotherapy in Advanced NSCLC ( Download)
- Progress in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors ( Download)
- Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma ( Download)
- The challenges of using biomarkers for immunotherapy ( Download)
- Immunotherapy Biomarkers ( Download)
- Immunotherapy Biomarkers and Patient Selection ( Download)
